Results of Operations and Financial Conditions. On August 12, 2026, Unicycive Therapeutics, Inc. issued a press release announcing its financial results for the second quarter ended June 30, 2026 and provided a business update. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K. The information disclosed under this Item 2.02, including Exhibit 99.1 hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 193…

Entry into a Material Definitive Agreement. As previously reported, Unicycive Therapeutics, Inc. (the “Company”) entered into a Sales Agreement, dated November 13, 2024, with Guggenheim Securities, LLC, as sales agent (the “Agent”) as amended by Amendment No. 1 to Sales Agreement dated November 14, 2025, between the Company and the Agent (as amended, the “Sales Agreement”), to sell shares of its common stock, par value $0.001 per share (the “Common Stock”), having an aggregate offering price…

Results of Operations and Financial Conditions. On May 12, 2026, Unicycive Therapeutics, Inc. issued a press release announcing its financial results for the first quarter ended March 31, 2026 and provided a business update. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K. The information disclosed under this Item 2.02, including Exhibit 99.1 hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934,…

Director — Gaurav Aggarwal: Dr. Gaurav Aggarwal resigned from the Board of Directors without any disagreement with the Company.

Results of Operations and Financial Conditions. On March 30, 2026, Unicycive Therapeutics, Inc. issued a press release announcing its financial results for the full year ended December 31, 2025 and provided a business update. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K. The information disclosed under this Item 2.02, including Exhibit 99.1 hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934,…

Results of Operations and Financial Conditions. On November 12, 2025, Unicycive Therapeutics, Inc. issued a press release announcing its financial results for the three months ended September 30, 2025 and provided a business update. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K. The information disclosed under this Item 2.02, including Exhibit 99.1 hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act o…

Results of Operations and Financial Condition On October 28, 2025, Unicycive Therapeutics, Inc. (the “Company”) issued a press release that included information with respect to certain preliminary, unaudited financial results of the Company. While the Company has not finalized its full financial results for the quarter ended September 30, 2025, the Company expects to report that it had approximately $42 million of cash and cash equivalents as of September 30, 2025. This estimate is preliminar…

Other Events On October 28, 2025, the Company issued a press release announcing an update from its meeting with the U.S. Food and Drug Administration and timing of the resubmission of its New Drug Application for Oxylanthanum Carbonate following receipt of a Complete Response Letter on June 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

Other Events. On August 15, 2025, Unicycive Therapeutics, Inc. (the “Company”) became aware of a lawsuit purporting to be a securities class action which was filed in United States District Court for the Northern District of California against the Company and certain of its officers. This action alleges violations of the federal securities laws in connection with public statements by the Company relating to its new drug application for oxylanthanum carbonate phosphate binder for the treatment…

Results of Operations and Financial Conditions. On August 14, 2025, Unicycive Therapeutics, Inc. issued a press release announcing its financial results for the three months ended June 30, 2025 and provided a business update. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K. The information disclosed under this Item 2.02, including Exhibit 99.1 hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934,…

Other Events . On June 30, 2025, Unicycive Therapeutics, Inc. (the “Company”) issued a press release announcing that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter for its New Drug Application (NDA) for oxylanthanum carbonate (OLC) to treat hyperphosphatemia in patients with chronic kidney disease on dialysis. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference herein. While the Company ha…

Results of Operations and Financial Condition The information set forth below in the second paragraph of

Material Modification to Rights of Security Holders. To the extent required by

Results of Operations and Financial Conditions. On May 14, 2025, Unicycive Therapeutics, Inc. issued a press release announcing its financial results for the three months ended March 31, 2025 and provided a business update. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K. The information disclosed under this Item 2.02, including Exhibit 99.1 hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, a…

Results of Operations and Financial Conditions. On March 31, 2025, Unicycive Therapeutics, Inc. issued a press release announcing its financial results for the full year ended December 31, 2024 and provided a business update. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K. The information disclosed under this Item 2.02, including Exhibit 99.1 hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934,…

Results of Operations and Financial Conditions. On November 13, 2024, Unicycive Therapeutics, Inc. issued a press release announcing its financial results for the three months ended September 30, 2024 and provided a business update. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K. The information disclosed under this Item 2.02, including Exhibit 99.1 hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act o…

Results of Operations and Financial Conditions. On August 14, 2024, Unicycive Therapeutics, Inc. issued a press release announcing its financial results for the three months ended June 30, 2024 and provided a business update. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K. The information disclosed under this Item 2.02, including Exhibit 99.1 hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934,…

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On July 9, 2024, Unicycive Therapeutics, Inc. (the “Company”) received written notice (the “ Notice ”) from the Nasdaq Stock Market, LLC (“ Nasdaq ”) indicating that the bid price for the Company’s common stock (the “Common Stock”), for the last 30 consecutive business days, had closed below the minimum $1.00 per share and, as a result, the Company is not in compliance with the $1.00 minimum b…

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On July 9, 2024, Unicycive Therapeutics, Inc. (the “Company”) received written notice (the “ Notice ”) from the Nasdaq Stock Market, LLC (“ Nasdaq ”) indicating that the bid price for the Company’s common stock (the “Common Stock”), for the last 30 consecutive business days, had closed below the minimum $1.00 per share and, as a result, the Company is not in compliance with the $1.00 minimum b…

Entry into a Material Definitive Agreement. On June 26, 2024 (the “Effective Date”), Unicycive Therapeutics, Inc. (the “Company”) entered into the First Amendment to Manufacturing and Supply Agreement with Shilpa Medicare, Ltd., an Indian corporation (“Shilpa”) (the “Amendment”). The Company and Shilpa are parties to that certain Manufacturing and Supply Agreement, dated as of October 31, 2020 (the “Agreement”) pursuant to which Shilpa provides certain development, manufacturing, supply and o…

Results of Operations and Financial Conditions. On May 13, 2024, Unicycive Therapeutics, Inc. issued a press release announcing its financial results for the three months ended March 31, 2024 and provided a business update. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K. The information disclosed under this Item 2.02, including Exhibit 99.1 hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, a…

Results of Operations and Financial Conditions. On March 28, 2024, Unicycive Therapeutics, Inc. issued a press release announcing its financial results for the year ended December 31, 2023 and provided a business update. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K. The information disclosed under this Item 2.02, including Exhibit 99.1 hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as a…

The Exchanged Preferred and the Amended Warrants are being issued pursuant to the exemption from registration provided by Section 4(a)(2) and Rule 3(a)(9) of the Securities Act of 1933, as amended (the “ Securities Act ”). The securities underlying the Exchanged Preferred and the Amended Warrants (including the Common Stock issuable upon conversion of the Series A-2 Prime Convertible Preferred Stock, Series A-3 Convertible Preferred Stock, the Series A-4 Convertible Preferred Stock and the Se…

The Series B Preferred Stock are being sold and, upon conversion, the Common Stock will be issued without registration under the Securities Act, in reliance on the exemptions provided by Section 4(a)(2) of the Securities Act as a transaction not involving a public Private Placement and Rule 506 promulgated under the Securities Act as sales to accredited investors, and in reliance on similar exemptions under applicable state laws.

Other Events. On March 13, 2024, the Company issued a press release announcing the Private Placement, a copy of which is attached hereto as Exhibit 99.1 and incorporated herein by reference.